290 related articles for article (PubMed ID: 38349185)
1. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.
Zeng Q; Antia A; Casorla-Perez LA; Puray-Chavez M; Kutluay SB; Ciorba MA; Ding S
mBio; 2024 Mar; 15(3):e0228723. PubMed ID: 38349185
[TBL] [Abstract][Full Text] [Related]
2. Calpain-2 mediates SARS-CoV-2 entry and represents a therapeutic target.
Zeng Q; Antia A; Puray-Chavez M; Kutluay SB; Ding S
bioRxiv; 2022 Nov; ():. PubMed ID: 36482976
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
Elife; 2020 Oct; 9():. PubMed ID: 33103998
[TBL] [Abstract][Full Text] [Related]
4. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.
Verma D; Church TM; Swaminathan S
J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968
[TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
7. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
Rowland R; Brandariz-Nuñez A
Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
[TBL] [Abstract][Full Text] [Related]
9. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
10. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
11. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
12.
Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
[TBL] [Abstract][Full Text] [Related]
13. Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells.
Chen J; Fan J; Chen Z; Zhang M; Peng H; Liu J; Ding L; Liu M; Zhao C; Zhao P; Zhang S; Zhang X; Xu J
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34873039
[TBL] [Abstract][Full Text] [Related]
14. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
16. P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation.
Liu M; Lu B; Li Y; Yuan S; Zhuang Z; Li G; Wang D; Ma L; Zhu J; Zhao J; Chan CC; Poon VK; Chik KK; Zhao Z; Xian H; Zhao J; Zhao J; Chan JF; Zhang Y
Signal Transduct Target Ther; 2023 Oct; 8(1):385. PubMed ID: 37806990
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
Kettunen P; Lesnikova A; Räsänen N; Ojha R; Palmunen L; Laakso M; Lehtonen Š; Kuusisto J; Pietiläinen O; Saber SH; Joensuu M; Vapalahti OP; Koistinaho J; Rolova T; Balistreri G
J Virol; 2023 Apr; 97(4):e0014423. PubMed ID: 37039676
[TBL] [Abstract][Full Text] [Related]
19. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
20. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
